Cargando…

Emergence of human CMV-induced NKG2C(+) NK cells is associated with CD8(+) T-cell recovery after allogeneic HCT

Cytomegalovirus (CMV) infection is associated with the expansion of a mature NKG2C(+)FcεR1γ(−) natural killer (NK) cell population. The exact mechanism underlying the emergence of NKG2C(+) NK cells, however, remains unknown. Allogeneic hematopoietic cell transplantation (HCT) provides an opportunity...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Ploeg, Kattria, Sottile, Rosa, Kontopoulos, Theodota, Shaffer, Brian C., Papanicolaou, Genovefa A., Maloy, Molly A., Cho, Christina, Robinson, Kevin S., Perales, Miguel-Angel, Le Luduec, Jean-Benoît, Hsu, Katharine C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561005/ https://www.ncbi.nlm.nih.gov/pubmed/37196646 http://dx.doi.org/10.1182/bloodadvances.2022008952

Ejemplares similares

91. Differential Impact of Cytomegalovirus (CMV) Donor (D) Serostatus on Rates and Kinetics of CMV Viremia among CMV Seropositive Recipients (R+) of Ex vivo T-cell Depleted (TCD) and Unmodified (CONV) Hematopoietic Cell Transplants (HCT)
por: Stern, Anat, et al.
Publicado: (2019)

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2023)

1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience
por: Zavras, Phaedon D, et al.
Publicado: (2019)

Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG
por: Turki, Amin T., et al.
Publicado: (2021)

595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study
por: Han, Gyuri, et al.
Publicado: (2021)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation
por: Petersdorf, Effie W., et al.
Publicado: (2023)

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
por: Shouval, Roni, et al.
Publicado: (2022)

1104. Risk Factors and Outcomes of Refractory and/or Resistant Cytomegalovirus (CMV) Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Karantoni, Eleni, et al.
Publicado: (2020)

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors
por: Bashey, Asad, et al.
Publicado: (2023)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
por: Geerlinks, Ashley V., et al.
Publicado: (2023)

Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation
por: Nunez, Lina, et al.
Publicado: (2022)

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
por: Menghrajani, Kamal, et al.
Publicado: (2022)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD
por: Chan, Yuen Ling Tracey, et al.
Publicado: (2017)

Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation
por: Miyata, Masahiro, et al.
Publicado: (2023)

Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation
por: Martin, Paul J., et al.
Publicado: (2022)

EASIX-1year and late mortality after allogeneic stem cell transplantation
por: Kordelas, Lambros, et al.
Publicado: (2023)

An Unusual Presentation of Nocardiosis in an Allogeneic Transplant Recipient
por: Ibrahim, Uroosa, et al.
Publicado: (2016)

Treatment of allosensitized patients receiving allogeneic transplantation
por: Ciurea, Stefan O., et al.
Publicado: (2021)

Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
por: Noviello, Maddalena, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
por: Murthy, Hemant S., et al.
Publicado: (2023)

Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
por: Chiesa, Robert, et al.
Publicado: (2022)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant
por: Rubinstein, Jeremy D., et al.
Publicado: (2022)

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades
por: Nishiwaki, Satoshi, et al.
Publicado: (2022)

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant
por: Pérez-Valencia, Amanda Isabel, et al.
Publicado: (2022)

Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic
por: Devine, Steven M., et al.
Publicado: (2023)

Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation
por: Kanaan, Sami B., et al.
Publicado: (2023)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques
por: Ram, Daniel R., et al.
Publicado: (2018)

Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation
por: Ren, Xiying, et al.
Publicado: (2021)

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects
por: Patterson, Michael T., et al.
Publicado: (2023)

Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children
por: Masetti, Riccardo, et al.
Publicado: (2023)

Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia
por: Shahid, Sanam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5626m1j93ve6ropp8rppj36ott